Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rotavirus vaccine - PATH

Drug Profile

Rotavirus vaccine - PATH

Alternative Names: Trivalent P2-VP8; Trivalent rotavirus P2-VP8 subunit vaccine - SK Bioscience; Trivalent rotavirus vaccine - SK Bioscience; TV P2-VP8

Latest Information Update: 05 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PATH
  • Class Rotavirus vaccines; Subunit vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rotavirus infections

Most Recent Events

  • 09 Sep 2022 PATH and SK Bioscience completes a phase II trial for Rotavirus infections (In neonates, In infants, Prevention) in South Africa (IM) (NCT04344054)
  • 08 Apr 2021 PATH and SK Bioscience re-initiates a phase III trial for Rotavirus infections (Prevention, In infants) in Zambia (IM) that was temporarily suspended due to COVID-2019(NCT04010448)
  • 22 Feb 2021 Phase-II clinical trials in Rotavirus infections (In infants, In neonates, Prevention) in South Africa (IM) (NCT04344054)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top